Pivotal new waterfront science lab set to cast off in The Medical Center

LEVIT GREEN BLOOMS

The new building features a waterfront, wharf environment. Rendering courtesy of Hines

The first step of a pivotal new Medical Center district has been revealed. International real estate firm Hines and partner 2ML Real Estate Interests have unveiled the first look at the initial building at Levit Green.

This new, 53-acre life science complex will sit adjacent to the Texas Medical Center. The five-story, 270,000-square-foot Phase I building is designated for life sciences; JLL has been selected as leasing representative for the project, per a press release.

Sitting on the first of several lakes that create Levit Green's oasis, Phase I boasts a sprawling boardwalk environment. Tenants will enjoy waterfront amenities including a 5,800-square foot fitness center and outdoor garden, 7,000-square-foot conference center, 3,500 square feet of café and restaurant space, and on-site parking.

Ground-floor plans include more than 25,000 square feet of lab incubator space, which will provide entrepreneurs and early-stage life science companies top-tier, strategically located laboratory and office space as well as networking opportunities, per a release.

As for the building itself, amenities include: 100-percent-redundant emergency power, enhanced structural vibration attenuation, and augmented mechanical systems. Work on Phase I is slated to begin in the second quarter of this year, with occupancy beginning in Q4.

The 53-acre Levit Green proposed site. Rendering courtesy of Hines

According to data, Houston produces more medical doctorates than any other MSA and generates more research doctorates in the key life science subject areas of biology and physical sciences (chemistry, physics, etc.) than San Francisco, San Diego, and Seattle. Thus, Levit Green promises to solve the real estate demands of arguably the nation's life science capital.

"Houston is quickly emerging as a top life science cluster city and has been able to do so without the purpose-built product established in other locations," said John Mooz, senior managing director at Hines, in a statement. "The Phase I project at Levit Green has been thoughtfully designed from the inside out to include features that are required of a top-tier research environment. We are excited to deliver the highest quality of building that will enable industry leaders to better conduct their critical research."

------

This article originally ran on CultureMap.

The Levit Green development will feature office, research, residential, retail, and dining components, along with outdoor amenities and green space. Image courtesy of Hines

New development announced to rise alongside Houston's Texas Medical Center

now building

Two Houston-based commercial real estate companies — Hines Interests LP and 2ML Real Estate Interests Inc. — have teamed up to develop a 52-acre life-sciences-anchored, mixed-use project adjacent to the Texas Medical Center.

The Levit Green development will feature office, research, residential, retail, and dining components, along with outdoor amenities and green space. In a June 15 release, the developers say Levit Green will sit "at the epicenter of Houston's biotech, corporate life sciences, and medical research hub."

Levit Green will be near the planned TMC³ biomedical research campus. The Hines-2ML project will be built at the northwest corner of Holcombe Boulevard and U.S. Highway 288 on an industrial site that was the headquarters of The Grocery Supply Co. Inc., the predecessor of 2ML.

Being built at a cost of $1.5 billion, the 1.5 million-square-foot, 36-acre TMC³ campus is set for completion in 2022.

"At 15.5 percent, Houston has one of the highest five-year growth rates in life sciences establishments in the United States. Impressive advancements in therapeutics, science, and innovation are driving demand for real estate," John Mooz, senior managing director of Hines, says in the release.

Privately held Hines is a real estate investor, developer, and manager whose portfolio comprises $133.3 billion in assets across 24 countries.

Because Levit Green remains in the master-planning phase, the developers aren't able to provide the project's square footage. They plan to break ground once design work for the initial buildings is finished. The developers decline to disclose a price tag for the project.

"Given the explosive growth and investment in innovation in the life science sector, there is an intense need for state-of-the-art facilities which enable the research required to bring these planned advances into being," Mooz tells InnovationMap in a statement. "As Houston is an ascending life science cluster city, which also includes the world's largest medical center, the need to create facilities that enhance research and development was, to us, obvious."

An initial parcel for Levit Green was purchased by Joe Levit, founder of The Grocers Supply Co., which grew into a major independent wholesaler of groceries in the U.S. and the largest supplier of Hispanic groceries in the U.S. The Levit family owns 2ML.

"Our family has deep roots in the neighborhood, and we believe this development will add tremendous value to the area and the Texas Medical Center," Max Levit, president of 2ML, says in the release.

The Levits entered the retail sector with the purchase of the Gerland's Inc. and Fiesta Mart Inc. grocery chains. In 2014, the family sold its wholesale business and the Grocers Supply name. The following year, the company sold Gerland's and Fiesta Mart.

In conjunction with the sale of the wholesale business and the brand, The Grocers Supply Co. changed its name to 2ML Real Estate Interests. The renamed company controls a portfolio of more than 5.2 million square feet of warehouses, shopping centers, supermarkets, and office buildings. The bulk of 2ML's portfolio is in the Houston area.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

View All Listings